Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (266) 266
life sciences & biomedicine (259) 259
humans (223) 223
diabetes (138) 138
male (127) 127
endocrinology & metabolism (126) 126
female (113) 113
biological and medical sciences (111) 111
medical sciences (106) 106
type 2 diabetes (87) 87
middle aged (84) 84
diabetes mellitus, type 2 - drug therapy (74) 74
risk factors (69) 69
adult (62) 62
aged (62) 62
endocrinopathies (61) 61
diabetes. impaired glucose tolerance (60) 60
endocrine pancreas. apud cells (60) 60
diabetes mellitus (58) 58
hypoglycemic agents - therapeutic use (54) 54
abridged index medicus (53) 53
insulin (51) 51
animals (50) 50
diabetes mellitus, type 2 - complications (42) 42
etiopathogenesis. screening. investigations. target tissue resistance (42) 42
analysis (39) 39
cardiovascular system & cardiology (39) 39
blood glucose - metabolism (38) 38
care and treatment (37) 37
treatment outcome (35) 35
general & internal medicine (34) 34
research (34) 34
medicine, general & internal (32) 32
rats (31) 31
cardiac & cardiovascular systems (30) 30
diabetics (29) 29
cardiovascular disease (28) 28
cardiovascular diseases (28) 28
double-blind method (28) 28
hyperglycemia (28) 28
mortality (28) 28
clinical trials (27) 27
health aspects (27) 27
insulin resistance (27) 27
glucose (26) 26
obesity (25) 25
physics (25) 25
education (24) 24
hypertension (24) 24
pharmacology. drug treatments (24) 24
insulin - administration & dosage (23) 23
metabolic diseases (23) 23
adamantane - analogs & derivatives (22) 22
diabetes mellitus, type 2 - blood (22) 22
patient outcomes (22) 22
advertising (21) 21
appliances for teaching, or communicating with, the blind,deaf or mute (21) 21
arrangements, systems or apparatus for checking not providedfor elsewhere (21) 21
checking-devices (21) 21
complications and side effects (21) 21
cryptography (21) 21
diagrams (21) 21
display (21) 21
educational or demonstration appliances (21) 21
generating random numbers (21) 21
globes (21) 21
insulin - therapeutic use (21) 21
peripheral vascular disease (21) 21
planetaria (21) 21
registering or indicating the working of machines (21) 21
seals (21) 21
time or attendance registers (21) 21
voting or lottery apparatus (21) 21
insulin - blood (20) 20
pharmacology & pharmacy (20) 20
diabetes mellitus, type 2 - epidemiology (19) 19
diabetes therapy (19) 19
hypoglycemic agents - administration & dosage (19) 19
drug therapy (18) 18
glucose tolerance test (18) 18
internal medicine (18) 18
patients (18) 18
medical research (17) 17
miscellaneous (17) 17
public health. hygiene (17) 17
public health. hygiene-occupational medicine (17) 17
hypoglycemic agents - adverse effects (16) 16
blood glucose - analysis (15) 15
blood glucose - drug effects (15) 15
blood pressure (15) 15
calculating (15) 15
cardiovascular diseases - prevention & control (15) 15
computing (15) 15
counting (15) 15
dapagliflozin (15) 15
dosage and administration (15) 15
heart attacks (15) 15
heart failure (15) 15
hypoglycemia (15) 15
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (526) 526
French (10) 10
Hebrew (6) 6
German (4) 4
Russian (2) 2
Chinese (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Sitagliptin: A viewpoint by Itamar Raz
by Raz, Itamar
Drugs (New York, N.Y.), ISSN 0012-6667, 2007, Volume 67, Issue 4, p. 598
Hypoglycemic Agents - therapeutic use | Animals | Diabetes Mellitus, Type 2 - physiopathology | Humans | Pyrazines - therapeutic use | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Triazoles - therapeutic use
Journal Article
Details down arrow
2. Full Text Therapy in the early stage: Incretins
by Cernea, Simona and Itamar, R.A.Z
Diabetes care, ISSN 0149-5992, 05/2011, Volume 34, Issue 2, pp. S264 - S271
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Incretins - metabolism | Diabetes Mellitus, Type 2 - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Humans | Insulin resistance | Hyperglycemia | Biosynthesis | Diabetes | Hormones | Apoptosis | Index Medicus | Diabetes Treatments
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes
by Tkáč, Ivan and Raz, Itamar
Diabetes care, ISSN 0149-5992, 02/2017, Volume 40, Issue 2, pp. 284 - 286
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Sitagliptin Phosphate - administration & dosage | Acute Disease | Piperidines - administration & dosage | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Pancreatitis - epidemiology | Dipeptides - adverse effects | Humans | Pancreatitis - chemically induced | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Incidence | Randomized Controlled Trials as Topic | Dipeptides - administration & dosage | Uracil - administration & dosage | Uracil - adverse effects | Piperidines - adverse effects | Adamantane - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Adamantane - adverse effects | Adamantane - analogs & derivatives | Sitagliptin Phosphate - adverse effects | Uracil - analogs & derivatives | Type 2 diabetes | Diabetics | Treatment outcome | Care and treatment | Analysis | Pancreatitis | Health aspects | Risk factors | Cardiovascular system | Clinical trials | Medical treatment | Risk assessment | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Guideline approach to therapy in patients with newly diagnosed type 2 diabetes
by Raz, Itamar
Diabetes care, ISSN 0149-5992, 08/2013, Volume 36, Issue 2, pp. S139 - S144
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Diabetes. Impaired glucose tolerance | Miscellaneous | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Hypoglycemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - diagnosis | Drug Therapy, Combination - methods | Algorithms | Drug Therapy, Combination - utilization | Guideline Adherence | Hypoglycemic Agents - economics | Humans | Diabetes Mellitus, Type 2 - therapy | Diabetes Mellitus, Type 2 - economics | Hypoglycemic Agents - classification | Practice Guidelines as Topic | Type 2 diabetes | Complications and side effects | Care and treatment | Patient outcomes | Cardiovascular diseases | Pharmaceutical industry | Diabetes therapy | Index Medicus | Diabetes Pathophysiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
by Zelniker, Thomas A and Wiviott, Stephen D and Raz, Itamar and Im, Kyungah and Goodrich, Erica L and Bonaca, Marc P and Mosenzon, Ofri and Kato, Eri T and Cahn, Avivit and Furtado, Remo H M and Bhatt, Deepak L and Leiter, Lawrence A and McGuire, Darren K and Wilding, John P H and Sabatine, Marc S
The Lancet (British edition), ISSN 0140-6736, 01/2019, Volume 393, Issue 10166, pp. 31 - 39
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Diabetic Nephropathies - etiology | Cardiovascular Diseases - prevention & control | Humans | Primary Prevention - methods | Diabetes Mellitus, Type 2 - drug therapy | Secondary Prevention - methods | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Prevention | Type 2 diabetes | Chronic diseases | Kidney diseases | Analysis | Heart attack | Myocardial infarction | Fees & charges | Renal function | Heart attacks | Laboratories | Clinical trials | Cardiovascular disease | Systematic review | Evidence-based medicine | Heterogeneity | Atherosclerosis | Data search | Cardiology | Diabetes mellitus (non-insulin dependent) | Heart diseases | Heart failure | Cerebral infarction | Stroke | Research & development--R&D | Diabetes mellitus | Mortality | Health risks | Patients | Coronary artery disease | Meta-analysis | Inhibitors | Sodium | Arteriosclerosis | Renal failure | Death | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Insulin Therapy: Future Perspectives
by Cernea, Simona and Raz, Itamar
American journal of therapeutics, ISSN 1075-2765, 01/2020, Volume 27, Issue 1, pp. E121 - E132
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Hypoglycemic Agents - therapeutic use | Drug Administration Routes | Humans | Blood Glucose | Insulin - administration & dosage | Diabetes Mellitus, Type 1 - drug therapy | Drug Delivery Systems | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Cost-Benefit Analysis | Glycated Hemoglobin A | Quality of Life | Insulin Infusion Systems | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text SGLT2 inhibitors and heart failure - clinical implications
by Raz, Itamar and Cahn, Avivit
Nature reviews cardiology, ISSN 1759-5002, 04/2016, Volume 13, Issue 4, pp. 185 - 186
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1cTargets? Diabetes Care 2016;38:e145–e146
by Raz, Itamar and Cahn, Avivit
Diabetes care, ISSN 0149-5992, 12/2016, Volume 39, Issue 12, pp. e227 - e227
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Do patient characteristics impact decisions by clinicians on hemoglobina1c targets? Diabetes Care 2016;38: E145-e146
by Raz, Itamar and Cahn, Avivit
Diabetes care, ISSN 0149-5992, 2016, Volume 39, Issue 12, p. e227
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum
by Cefalu, William T and Kaul, Sanjay and Gerstein, Hertzel C and Holman, Rury R and Zinman, Bernard and Skyler, Jay S and Green, Jennifer B and Buse, John B and Inzucchi, Silvio E and Leiter, Lawrence A and Raz, Itamar and Rosenstock, Julio and Riddle, Matthew C
Diabetes care, ISSN 0149-5992, 01/2018, Volume 41, Issue 1, pp. 14 - 31
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Glycoside Hydrolase Inhibitors - therapeutic use | Male | Clinical Trials, Phase III as Topic | Glucagon-Like Peptide-1 Receptor - metabolism | Endpoint Determination | Female | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 - metabolism | Mortality | Risk Factors | Sodium-Glucose Transporter 2 Inhibitors | Treatment Outcome | Randomized Controlled Trials as Topic | Cardiovascular System - metabolism | Aged | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide-1 Receptor - agonists | Insulin - therapeutic use | Clinical Trials, Phase II as Topic | Drugs | Prescription drugs | Diabetes mellitus | Editors | Clinical trials | Cardiovascular disease | Diabetes | Pharmaceutical industry | Drug development | Diabetes mellitus (non-insulin dependent) | Index Medicus | 0201 | Expert Forum
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Heart failure: SGLT2 inhibitors and heart failure-clinical implications
by Raz, Itamar and Cahn, Avivit
Nature reviews cardiology, ISSN 1759-5002, 04/2016, Volume 13, Issue 4, pp. 185 - 186
Hypoglycemic Agents - therapeutic use | Hospitalization | Diabetes Mellitus, Type 2 - drug therapy | Humans | Heart Failure - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Reply
by Wiviott, Stephen D and Raz, Itamar and Sabatine, Marc S
The New England journal of medicine, ISSN 0028-4793, 05/2019, Volume 380, Issue 19, pp. 1881 - 1882
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Diabetes Mellitus, Type 2 | Benzhydryl Compounds | Humans | Glucosides | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Impact of the U.S. food and drug administration cardiovascular assessment requirements on the development of novel antidiabetes drugs
by Hirshberg, Boaz and Raz, Itamar
Diabetes care, ISSN 0149-5992, 05/2011, Volume 34, Issue 2, pp. S101 - S106
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Clinical Trials, Phase III as Topic | United States | Humans | Cardiovascular System - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | United States Food and Drug Administration - legislation & jurisprudence | Clinical Trials, Phase II as Topic | Type 2 diabetes | Safety regulations | Hypoglycemic agents | Drug therapy | Diabetes therapy | Clinical trials | Cardiovascular disease | Heart attacks | Diabetes | Mortality | Index Medicus | Diabetes, Obesity and Hypertension Outcome Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes
by Aharon-Hananel, Genya and Raz, Itamar
Expert opinion on pharmacotherapy, ISSN 1465-6566, 05/2019, Volume 20, Issue 7, pp. 781 - 790
Type 2 diabetes | Tofogliflozin | safety and efficacy | SGLT-2 inhibitors | cardiovascular outcome | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Glycated Hemoglobin A - analysis | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Kidney Diseases - pathology | Humans | Half-Life | Kidney Diseases - drug therapy | Ketosis - etiology | Treatment Outcome | Clinical Trials as Topic | Glucosides - pharmacokinetics | Sodium-Glucose Transporter 2 Inhibitors - pharmacokinetics | Benzhydryl Compounds - adverse effects | Hypoglycemia - etiology | Glucosides - therapeutic use | Diabetes Mellitus, Type 2 - pathology | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Benzhydryl Compounds - pharmacokinetics | Glucosides - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights